NPP

Nandrolone phenylpropionate (Durabolin) was the comparator to drostanolone propionate specifically in the perimenopausal arm of a historical 1968-1972, three-arm breast-cancer trial, with reported response rates of 39% for Durabolin and 34.5% for drostanolone propionate in that subgroup; the abstract does not report subgroup sample sizes or a significance test for this comparison. This confirms studied human use of that ester, but not modern athletic benefits or the half-life of the separate decanoate ester.^[1]

• Historical oncology study with limited abstract methods; different ester from nandrolone decanoate.
• Abstract-checked; no qualified clinical review.
• A possible numerical advantage for nandrolone phenylpropionate over drostanolone propionate in this one subgroup is not a proven difference; no denominators or P-value are reported for it.

A study of male weightlifters associated long-term mixed AAS exposure with lower left-ventricular function and greater coronary plaque volume than in non-users. The observational design cannot isolate an individual steroid or prove a precise risk of heart attack.^[3]

• Class-context evidence from selected male weightlifters; residual confounding and uncertain historical exposures remain.
• This finding and the interaction file's "safety-aas-cardiovascular" note rest on the same single study, held under two source records. Seeing both is not two studies agreeing.

The HAARLEM echocardiography cohort found increased left-ventricular mass and reduced function during mixed AAS use. Left-ventricular mass and the E/A ratio returned to baseline at follow-up, when only 25 of 31 participants had recovery imaging. These group findings cannot promise that every person or repeated exposure recovers.^[4]

• Small cohort, coexposures and missing follow-up; no clinical-event or molecule-specific risk estimate.

A cross-sectional study of male weightlifters associated long-term illicit AAS use with impaired cardiac function and more coronary plaque. The study cannot establish the risk from one particular compound, dose or combination.^[3]

• This note and the compound records' "general-anadrol-safety-86" finding rest on the same single study, held under two source records. Seeing both is not two studies agreeing.
• Observational evidence, self-reported mixed exposures and potential confounding; not a comparison of medically indicated testosterone treatment.
• This is the same underlying study cited at full-text scope elsewhere in the site (content/evidence/general.ts "general-aas-cardiovascular-full"); it is one single source, not independent corroboration.

FDA reports serious liver injury and other serious reactions involving steroid or steroid-like bodybuilding products. It advises immediately consulting a healthcare professional, including before abrupt cessation, because of dangerous withdrawal problems that can arise from quickly stopping such products.^[5]

• General product safety communication, not an incidence estimate for every listed steroid.

In the HAARLEM cohort of men using mixed anabolic-androgenic steroids, testosterone and sperm recovery differed. The final visit was one year after cycle start, not one year after cessation, and some abnormal final results were already present at baseline. The study did not measure pregnancy or live birth and does not provide a universal recovery deadline.^[2]

• Class-context evidence: mixed exposures cannot isolate any individual molecule or ester, and follow-up was too short to characterize all recovery.
• Final hormone and semen denominators differ; attrition and resumed use limit recovery inference.

Long-term illicit AAS exposure was associated with myocardial dysfunction and greater coronary plaque in male weightlifters. Concern about combining AAS follows from this class evidence; the incremental risk of any two steroids was not measured, and the paper does not name or compare specific steroid combinations.^[3]

• Observational, mixed self-reported exposure; no pair-specific causal estimate.
• This is the same underlying study cited at full-text scope elsewhere in the site (general.ts "general-aas-cardiovascular-full"); it is one single source, not independent corroboration.

FDA warns that people who “stack” steroid-like bodybuilding products with other products, including stimulants, may be at greater risk for serious and life-threatening reactions. This broad warning does not establish the effect or severity of an individual compound pair.^[5]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.

A review of testosterone-treatment studies found increased hemoglobin and hematocrit. Extrapolating to combined anabolic steroids suggests a possible overlapping effect, but the review did not establish pair-specific thrombosis risk.^[6]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.

Testosterone-related hematocrit increases and tamoxifen/raloxifene thromboembolic findings come from different study populations. They motivate a possible overlapping concern, not evidence of a measured thrombosis increase from the selected pair.^[6][7]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.

A controlled study in men given goserelin, testosterone gel and anastrozole linked estrogen deficiency to increased body fat and a contribution to reduced sexual function. Only anastrozole was studied; it does not establish the outcome of combining aromatase inhibitors generally, or of adding anastrozole specifically to a particular anabolic steroid.^[8]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.
• Exemestane and letrozole were not administered in this trial and do not inherit this observation; the compound scope and the corresponding rule's applicable IDs are narrowed to anastrozole (see interactionsFileNotes).